Tudorza Pressair generic
Tudorza Pressair is a chronic obstructive pulmonary disease (COPD) treatment drug owned by Astrazeneca. It contains aclidinium bromide as its active ingredient and was authorised for market use on 23 July, 2012. It is available in powder, metered;inhalation dosage forms.
When will Tudorza Pressair generic be available?
The generic version of Tudorza Pressair is likely to be released after the expiry of its last patent on 13 March, 2029. This date is subject to change if anyone else files a Para IV challenge against any of the Tudorza Pressair's patents.
Tudorza Pressair uses
The active ingredient in Tudorza Pressair, aclidinium bromide, is highly effective in the maintenance treatment of chronic obstructive pulmonary disease (COPD). aclidinium bromide works by helping the muscles around the airways in your lungs stay relaxed to prevent symptoms such as wheezing, cough, chest tightness, and shortness of breath.
Tudorza Pressair patent expiration
Astrazeneca's Tudorza Pressair has 5 patents. The last patent of Tudorza Pressair will expire on 13 March, 2029. The expired patent is titled 'Powder formulation disintegrating system and method for dry powder inhalers' and the expiration date was 7 August, 2022. Tudorza Pressair generic will depend on the status of the current patents. Below are the details of the patent: